Zura Bio Limited (ZURA)
| Market Cap | 35.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.19M |
| Shares Out | 5.14M |
| EPS (ttm) | -1.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 303,351 |
| Open | 6.60 |
| Previous Close | 6.60 |
| Day's Range | 6.55 - 7.00 |
| 52-Week Range | 4.87 - 37.55 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.00 (+187.77%) |
| Earnings Date | Aug 3, 2023 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ZURA stock is "Strong Buy" and the 12-month stock price forecast is $20.0.
News
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist
SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and ...
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: “ZURA”) (“Zura” or “Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for i...
Zura Bio Announces Appointment of Chief Scientific Officer
SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited announces the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.
Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp
SAN DIEGO--(BUSINESS WIRE)--Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced t...
JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited
LONDON--(BUSINESS WIRE)--JATT Acquisition Corp (NYSE: JATT) (“JATT”), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed busines...